Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Hongfu Cai"'
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectiveThis study focuses on assessing the cost-effectiveness of incorporating toripalimab alongside chemotherapy for the treatment of patients diagnosed with metastatic triple-negative breast cancer from the perspective of the Chinese healthcare s
Externí odkaz:
https://doaj.org/article/9ae1ac0befcf4b3f821d5a6f47396e7f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Chronic hepatitis B (CHB) is a worldwide infectious disease caused by hepatitis B virus (HBV). Optimizing antiviral treatment strategies could improve the functional cure (FC) rate of patients with CHB. This study aims to systematically
Externí odkaz:
https://doaj.org/article/ac9a0f1e46e949588bd2837654353da4
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThis study aims to systematically analyze the cost-effectiveness of the combination therapy comprising sugemalimab and chemotherapy in the management of advanced ESCC from the Chinese healthcare system perspective.MethodsAn advanced ESCC pa
Externí odkaz:
https://doaj.org/article/233f52af873743958357d7f245814df7
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectiveThe goal of this study is to compare the cost-effectiveness of tislelizumab and sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.MethodsA comprehensive cost-effectiveness analysis was undertaken within the fra
Externí odkaz:
https://doaj.org/article/6df4c5a306f4476997f64bab8119f813
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
BackgroundSerplulimab has shown promising results in the treatment of extensive-stage small cell lung cancer (ES-SCLC). This study aimed to evaluate the cost-effectiveness of serplulimab combination therapy compared to chemotherapy alone in patients
Externí odkaz:
https://doaj.org/article/e2218aab61604caab0199c555ce47457
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Objective The objective of this study is to evaluate the cost-effectiveness of adding pembrolizumab to the standard first-line therapy of advanced biliary tract cancer (BTC) with gemcitabine and cisplatin from the perspective of the Chinese
Externí odkaz:
https://doaj.org/article/99e587243d12472cbdcb37b6731b0f27
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThis study evaluated the cost-effectiveness of elacestrant (ELA) and standard-of-care (SOC) as second-/third-line treatment for pretreated estrogen receptor (ER)– positive/human epidermal growth factor receptor 2 (HER2)–negative advance
Externí odkaz:
https://doaj.org/article/132dceb8c4904c8a822f2149e640d963
Publikováno v:
BMJ Open, Vol 13, Iss 12 (2023)
Objective The objective of this study was to evaluate the cost-effectiveness of durvalumab in combination with chemotherapy compared with chemotherapy alone as first-line therapy for metastatic non-small-cell lung cancer (NSCLC) from the perspective
Externí odkaz:
https://doaj.org/article/fef8fb85f3ef46de9ae9477679343adc
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Objective: Cemiplimab combined with chemotherapy has emerged as a promising treatment option for advanced non-small cell lung cancer (NSCLC). Accordingly, this study has been conducted to evaluate the cost-effectiveness of this combination therapy in
Externí odkaz:
https://doaj.org/article/2541390f10a84ec3a287cda4516d2b3a
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Axicabtagene ciloleucel (Axi-cel) is the first Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) product approved in China for treating adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or a
Externí odkaz:
https://doaj.org/article/634117ff869f458197eafdca74fc4337